Vyvanse correction
Executive Summary
Shire's Vyvanse (lisdexamfetamine) is the first stimulant for attention deficit/hyperactivity disorder to include results of abuse liability studies in labeling, but like all stimulant medications, has the potential for abuse and is classified as a Schedule II Controlled Substance. As a result, Shire is not promoting Vyvanse as having a lower potential for abuse versus Adderall XR as reported in "The Pink Sheet," Jan. 19